University of Massachusetts Amherst

ScholarWorks@UMass Amherst
Chemical Engineering Faculty Publication Series

Chemical Engineering

2015

A cell–ECM screening method to predict breast
cancer metastasis
Lauren E. Barney
University of Massachusetts Amherst

E. C. Dandley
North Carolina State University

Lauren Jansen
University of Massachusetts Amherst

Nicholas G. Reich
University of Massachusetts Amherst

A. M. Mercurio
University of Massachusetts Medical School
See next page for additional authors

Follow this and additional works at: https://scholarworks.umass.edu/che_faculty_pubs
Part of the Chemical Engineering Commons
Recommended Citation
Barney, Lauren E.; Dandley, E. C.; Jansen, Lauren; Reich, Nicholas G.; Mercurio, A. M.; and Peyton, Shelly, "A cell–ECM screening
method to predict breast cancer metastasis" (2015). Integrative Biology. 844.
https://doi.org/10.1039/c4ib00218k

This Article is brought to you for free and open access by the Chemical Engineering at ScholarWorks@UMass Amherst. It has been accepted for
inclusion in Chemical Engineering Faculty Publication Series by an authorized administrator of ScholarWorks@UMass Amherst. For more
information, please contact scholarworks@library.umass.edu.

Authors

Lauren E. Barney, E. C. Dandley, Lauren Jansen, Nicholas G. Reich, A. M. Mercurio, and Shelly Peyton

This article is available at ScholarWorks@UMass Amherst: https://scholarworks.umass.edu/che_faculty_pubs/844

View Article Online

PAPER

View Journal | View Issue

A cell–ECM screening method to predict breast cancer metastasis†
L. E. Barney,a E. C. Dandley,b L. E. Jansen,a N. G. Reich,c A. M. Mercuriod and
S. R. Peyton*a

Breast cancer preferentially spreads to the bone, brain, liver, and lung. The clinical patterns of this tissuespecific spread (tropism) cannot be explained by blood flow alone, yet our understanding of what
mediates tropism to these physically and chemically diverse tissues is limited. While the microenvironment has been recognized as a critical factor in governing metastatic colonization, the role of
the extracellular matrix (ECM) in mediating tropism has not been thoroughly explored. We created a
simple biomaterial platform with systematic control over the ECM protein density and composition to
determine if integrin binding governs how metastatic cells diﬀerentiate between secondary tissue sites.
Instead of examining individual behaviors, we compiled large patterns of phenotypes associated with
adhesion to and migration on these controlled ECMs. In combining this novel analysis with a simple
biomaterial platform, we created an in vitro fingerprint that is predictive of in vivo metastasis. This rapid
biomaterial screen also provided information on how b1, a2, and a6 integrins might mediate metastasis in
patients, providing insights beyond a purely genetic analysis. We propose that this approach of screening
many cell–ECM interactions, across many different heterogeneous cell lines, is predictive of in vivo
behavior, and is much simpler, faster, and more economical than complex 3D environments or mouse
models. We also propose that when specifically applied toward the question of tissue tropism in breast
cancer, it can be used to provide insight into certain integrin subunits as therapeutic targets.

Insight, innovation, integration
We developed a high-throughput method to rapidly screen cell adhesion, motility, and growth factor responses on biomaterial surfaces. This approa ch is
analogous to systems biology, relying on cell phenotypes in lieu of genetics. We used this technique to reveal patterns of phenotypes associated with breast
cancer metastasis to possible tissue sites (bone, brain, lung). By comparing the phenotypic patterns between cell lines that metastasize to only one tissue site
with heterogeneous cell lines, we provide the first method to connect in vitro phenotype to in vivo fate. This method is successful without genetic analysis, yet it
also predicts outcomes related to integrin gene expression, potentially identifying new targets for tissue-specific metastasis.

Introduction
Breast cancer is the most common cancer in women, and metastasis is responsible for 90% of all cancer deaths. The microenvironment is a critical regulator of metastasis,1 and in vivo studies have
a
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provided insight into many microenvironment-mediated
mechanisms.2–6 However, these studies lack features of human
physiology, contain uncontrolled variables, and are often not
comparable across different mouse models. Thus, it is difficult
to parse the varying contributions of each factor, limiting the
broad applicability of these results. In contrast, in vitro models
can be either oversimplified,7 or highly complex, expensive, lowthroughput, and limited to highly specialized laboratories.8
Because metastasis remains both largely incurable and poorly
understood, there is a need for quick, cost-efficient in vitro
model systems with enough complexity to recapitulate certain
aspects of in vivo biology, while maintaining affordability and
efficiency.
Two-dimensional in vitro disease models are appropriately
low cost and simple, however, it is now generally appreciated

that two-dimensional cell behaviors are usually not conserved
in a three-dimensional context. One recent example of this is
work by Meyer et al., which showed that only two-dimensional
growth-factor induced membrane protrusion, but not any other
measured 2D motility parameter, accurately predicts 3D motility.9 This suggests that individual two-dimensional measurements will also not be predictive of even more complex in vivo
cell phenotypes. We suggest that a better approach may be to
avoid measurements of single, likely non-predictive metrics,
and instead, measure patterns of many phenotypes across
several conditions and several cell sources.10
Breast cancer metastasis is a clear candidate for this type of
approach because of its striking, yet unexplained, clinical
patterns of metastatic spread (tropism) to the bone, brain,
liver, and lung, but not to tissues such as the skin, heart,
uterus, or spleen.11,12 This tropism is hypothesized to depend
upon an unknown relationship between metastatic cells (the
seeds) and hospitable microenvironments (the soils).12 Because
the tissues often colonized by breast cancer cells each have a
distinct ECM, we posit that integrin binding to the ECM is one
feature that plays a critical role in the early stages of tissuespecific colonization and fate of extravasated cancer cells. It is
known that secondary site colonization requires activation of
integrin-mediated signaling,10,13–16 and several individual
integrins have been implicated in breast cancer metastasis
in vivo.17–20 However, this research is limited to metastasis at
a single tissue site, or to the effect of a single integrin, which is
not representative of the variety of cell–matrix interactions
simultaneously occurring in vivo during cell adhesion to a
secondary tissue site post-extravasation.
To this end, we created a novel biomaterial platform comprised of complex ECMs that can present any combination of fulllength proteins with high fidelity, reproducibility, and is
permanent during the cell culture period. We used this biomaterial to quantify how diﬀerent metastatic breast cancer cell
lines diﬀerentiate between secondary sites via integrin binding.
We compiled sixty-six distinct cell phenotypes associated with
cell adhesion and motility, both with and without epidermal
growth factor (EGF) stimulation. By collating all the responses
to each biomaterial ECM surface together, we created a phenotypic fingerprint of bone, brain, and lung metastasis, which is
both capable of distinguishing between genetically related
Table 1

tropic cell subpopulations, as well as predictive of the in vivo
metastasis of several other more heterogeneous cell lines,
thereby predicting in vivo fate with a quick in vitro screen. Taken
together, we propose this comprehensive analysis of cell–matrix
interactions as a tool to predict in vivo fate, as well as understand
the roles of integrins in tropism, thus providing insight toward
integrins as druggable targets for metastatic disease.

Results
Rapid biomaterial screening of cell–ECM interactions
The ECMs present in secondary tissues often recipient of breast
cancer colonization are each strikingly complex and distinct, 21
suggesting that cell–matrix interactions play a role in mediating
metastasis. Our goal here was to create a simple in vitro
biomaterial system to investigate the role of integrin binding
in breast cancer tropism. These biomaterial surfaces are glass
coverslips, modified via straightforward silane chemistry. They
present covalently coupled ECM proteins, and they remain
stable throughout the cell culture period (at least 72 hours).
This method can be used to couple any combination of fulllength proteins or peptides of interest, providing control over
cell–matrix interactions in a highly robust (Fig. S1, ESI†),
scalable, and facile process. It is particularly well suited to
observe integrin-mediated phenotypes of adherent cell lines,
and allows for functional investigation of real-time binding
to the ECM.
We used this approach to create three ECM microenvironments containing combinations of ECM proteins inspired by
the biochemical cues found at the in vivo tissues to which
breast cancer commonly spreads (Table 1). ECM at these tissues
has significant patient-to-patient variability,21 and can be remodelled
by both tumor and stromal cells over time.5,6 Our approach was
to determine if integrin binding alone, at early time points
(directly after extravasation), was suﬃcient to direct or predict
tissue-specific spread. Therefore, we created three biomaterial
surfaces containing combinations of ECM proteins that isolate
distinct integrin heterodimers, independently of the in vivo
heterogeneity, inspired by the ECM protein content of healthy
tissues at these sites.6,22–26

Composition of tissue-inspired biomaterial ECMs

ECM 1 (bone)

ECM 2 (brain)

ECM 3 (lung)

In vivo ECM density

High

Low

Moderate

In vivo ECM proteins

Collagen I
Fibronectin22
Osteopontin23

Laminin fibronectin collagen IV tenascins
proteoglycans24
Hyaluronic acid25

Fibronectin6
Collagens laminins elastin tenascin C proteoglycans26

In vitro ECM density

5 mg cm-2

1 mg cm-2

2 mg cm-2

In vitro ECM proteins

99% collagen I
1% osteopontin

50% fibronectin
25% vitronectin
20% tenascin C
5% laminin

33% laminin
33% collagen IV
15% collagen I
15% fibronectin
4% tenascin C

Fig. 1 Biomaterial platform for integrin-mediated phenotyping. (a) Breast cancer cell lines with their known in vivo metastatic tropisms.2–4,28–33 (b)
Three distinct ECM microenvironments regulate integrin binding. (c) Adhesion and motility phenotypes of the MDA-MB-231 cell line. Black: ECM 1; blue:
ECM 2; green: ECM 3.

As a first attempt to capture the heterogeneity of breast
cancer, we screened phenotypes associated with adhesion and
motility across a large panel of human cell lines that span the
clinical subtypes27 and metastatic specificity to the bone, brain,
and lung sites2–4,28–33 (Fig. 1a). We first measured spreading
and polarization of cells during initial adhesion to the ECMs,
quantifying time-dependent cell area, spreading rate, and
polarization of the population (Fig. 1c top and Fig. S2a–c, ESI†).
Next, we observed long-term motility, and quantified cell
migration speed, displacement, and chemotactic index (ratio of
displacement to path length, quantifies migration straightness)
(Fig. 1c bottom, Fig. S2d–f, ESI†). Altogether, 550 individual cell
observations were made per cell line on average (Fig. 1c and
Fig. S2, ESI†). In combination with an ELISA characterization of
the protein coupling (Fig. S1, ESI†), these measurements validate
the biomaterial platform as being able to elicit differential cell
line responses via integrin binding alone (Fig. S2, ESI†).
Phenotypic screen predicts tissue tropism in vivo
We hypothesized that an in vitro analysis of integrin-mediated
phenotypes would be capable of diﬀerentiating cell lines with
diﬀerent tropisms in vivo, reflecting the functional binding
interactions required for successful metastatic outgrowth. We
began by phenotyping three highly tropic subpopulations of the
MDA-MB-231 parental cell line, which were selected from in vivo
metastases by Massagué and colleagues.2–4 These geneti- cally
distinct MDA-MB-231 subpopulations each display strong
tropism to either the bone (‘‘bone tropic’’),2 brain (‘‘brain
tropic’’),4 or lung (‘‘lung tropic’’)3 in mice, and have been used
to identify genetic determinants of tissue-specific metastasis.
We found that these tissue-specific cell lines each responded to
the ECMs in unique ways (Fig. S3, ESI†).

We immediately noticed that for each diﬀerent measurement we took, the tropic cell lines were sensitive to the ECMs in
some cases, while insensitive in others. As an example, when
we quantified cell speed, the bone and brain tropic cell lines
had very diﬀerent cell speeds on each ECM surface, whereas the
lung tropic cells had similar cell speeds on all three ECMs. To
quantifiably demonstrate this, we applied a statistical tool
called the coeﬃcient of variation (CoV) to each set of measurements for a given cell line. This measurement quantifies
dispersion of a data set, and is computed by dividing the
standard deviation of a set of measurements by their mean.
In its application here, higher CoV values identify adhesion or
motility measurements where a cell line is highly sensitive to
the diﬀerent ECM surfaces (i.e., the relative standard deviation
of the measurements across each ECM is at least 10%). Because
these cell lines were created to exhibit strong in vivo metastasis
to one site, we first wanted to validate that this in vivo selectivity
was reflected in the in vitro cell–ECM screen. This CoV analysis
showed that each of the tropic cell subpopulations was significantly more sensitive to the ECMs than the parental cell line in
each of the adhesion and motility phenotypes we quantified
(Fig. S4a, ESI†), validating this approach.
Given that tropic cell lines have heightened sensitivity
to growth factors,34 we then quantified the change in each
adhesion and motility metric in response to EGF stimulation,
and found that the patterns of adhesion and motility across the
ECMs under normal and EGF-stimulated conditions varied
significantly between the tropic cell lines (Fig. S3, ESI†). The
eﬀect of EGF stimulation was especially striking in the tropic
cell adhesion. EGF slowed spreading and polarization of the
bone tropic cell line, while it increased the spreading rate of the
brain and lung tropic cell lines in an ECM-dependent fashion
(Fig. S3a–f, ESI†). Growth factor sequestration and growth

Fig. 2 Phenotypic fingerprint predicts bone, brain, and lung metastasis. Development of phenotypic fingerprints of bone, brain, and lung tropism from
patterns of integrin-mediated behavior. The (a) CoV, (b) EGF response, and (c) measurement ordering features were measured for each tropic cell line to
create a fingerprint. (d, e) Phenotypic fingerprints of tropic behavior (rows), with unique identifiers distinguished in dark colors. (d) Coeﬃcient of variation
for both the normal and EGF-stimulated conditions. Blue: high CoV (40.1); grey: low CoV (o0.1). (e) EGF response on each ECM. Red: increase
(fold change 4 1.15); grey: no change; green: decrease (fold change o 0.85). Pairwise ordering is provided in Fig. S4b (ESI†). Abbreviations: 1: ECM 1; 2:
ECM 2; 3: ECM 3; SR: spreading rate; A: area; P: polarization; S: speed; D: displacement; CI: chemotactic index. (f) Fingerprint of heterogeneous cell lines
overlaid onto tropic fingerprints allows for quantification of similarity to each tropic subpopulation. Colored boxes in overlaid cell lines identify features
shared with each tropic cell line. Black: bone tropic, red: brain tropic, blue: lung tropic. (g) In vitro tropism of the MDA-MB-231, SUM1315 MO2, BT549,
MDA-MB-468, HCC 1954, MDA-MB-361, SkBr3, and MCF7 cell lines. Black: bone tropic, red: brain tropic, blue: lung tropic. Bars represent the percentile
of the null distribution where each heterogeneous cell line lies, with error bars displaying the range of the respective percentile. High percentiles indicate
cell lines that are highly phenotypically tropic to a tissue site. Statistics shown above bars indicate that the cell line is significantly higher or lower than the
null distribution for the indicated tropism. Top labels: known in vivo tropism. Bottom labels: clinical subtype designation.

factor signalling both depend on the composition of the
ECM,35,36 which, in addition to the differences in the tropic
subpopulations, is likely one reason for the differences in EGF
responses.
With this collection of measurements, we sought to identify
all the phenotypes unique to cells metastasizing to the bone,
brain, or lung by compiling them en masse into a heat map.

All the adhesion and motility measurements were organized
across three separate classes of observable responses to the
ECMs (coeﬃcient of variation, response to EGF, and pairwise
ordering across ECMs, Fig. 2a–c).
As the first feature of these collective tropic phenotypes,
measurements in which the cell line was either highly sensitive
or insensitive to changes in the ECM were identified (Fig. 2a).

For example, the lung tropic line has a high spreading rate CoV,
whereas the brain tropic cell line has a low chemotactic index
CoV under EGF stimulation (Fig. 2a). We then quantified
whether each phenotype measured increased, decreased, or
remained unchanged in response to EGF stimulation on each
of the three ECMs (Fig. 2b). As examples, the lung tropic cells
increased their displacement with EGF stimulation, the bone
tropic cell line spreading area was unchanged, and the brain
tropic cell speed decreased upon EGF stimulation (Fig. 2b).
Finally, a pairwise statistical test was used to compare each
phenotype measured across each of the ECM surfaces, resulting
in an ‘‘ECM ordering’’ (Fig. 2c). As an example, the lung tropic
cell line has the statistically highest spreading rate on ECM 3,
followed by ECM 1, and is lowest on ECM 2 (Fig. 2c). In
contrast, the chemotactic index of the brain tropic cell line
was statistically equivalent on all ECMs.
We computed each of these features for all phenotypes and
compiled this into a heat map, creating a row for each tropic
cell line (Fig. 2d, e and Fig. S4b, ESI†). The color of each box
identifies the value of the phenotype for the respective cell line.
For the CoV measurement, highly sensitive measurements
(CoV 4 0.1) are identified with a blue box, while insensitive
measurements (CoV o 0.1) are identified with a grey box
(Fig. 2d). In Fig. 2e, EGF changes are determined via fold
change from the normal measurement. An increase (fold
change 4 1.15) is red, a decrease (fold change o 0.85) is green,
and no change (0.85 o fold change o 1.15) is grey (Fig. 2e). In
Fig. S4b (ESI†), for each pairwise comparison, a blue box indicates
that the first measurement is greater than the second, a grey box
indicates that they are equal, and a red box indicates that the
second measurement is greater than the first. Altogether, greater
than 1000 individual cell observations per tropic cell line were
quantified and compiled together to create sixty-six features of
integrin-mediated phenotypes for each tropic cell subpopulation
(Fig. 2d, e and Fig. S4b, ESI,† rows).
Looking down each column in Fig. 2d, e and Fig. S4b (ESI†),
we then identified behaviors that were specific to only one of the
three tropic cell lines. These instances are identified by a dark
shaded box of the appropriate color. Looking across each row,
thirteen measured phenotypes are unique to bone tropism, a
separate thirteen features are unique to lung tropism, and fifteen
to brain tropism (Fig. 2d, e and Fig. S4b, ESI†). Although no
singular adhesion or motility-associated phenotype was predictive of breast cancer tropism (not shown), this collective analysis
of many cell responses to ECMs combined to create phenotypic
fingerprints of bone, brain, and lung metastasis (Fig. 2d, e and
Fig. S4b, ESI†).
We repeated all these measurements using more heterogeneous cell lines with known, literature-reported metastasis
in vivo (Fig. 1a), and overlaid each cell line’s pattern of
behaviors onto the three fingerprints of tissue-specific metastasis we created (Fig. 2f). The measurements from each cell
line can be compared to the tissue-specific fingerprints generated from the tropic cell lines, resulting in a fractional
similarity value that represents the amount of unique phenotypic features shared with the cell lines that specifically

metastasize to either the bone, brain, or lung (Fig. S5a, ESI†).
As a control, a null distribution of 10 000 cell lines with
random phenotypes was generated in silico to represent ‘‘random metastasis’’ (Fig. S5a–d, ESI†). We determined how
similar the patterns were between each of the heterogeneous
cell lines and the bone, brain, and lung tropic fingerprints
(Fig. S5a, ESI†), and represented this as a percentile of the
respective null distribution (Fig. 2g).
With this in vitro method, we predicted the in vivo metastasis
of seven out of the eight heterogeneous cell lines tested. First,
the SUM1315 MO2 cell line, which metastasizes highly to
bone,37 most highly matches the bone fingerprint and is clearly
anti-brain and anti-lung tropic. Both the MDA-MB-46833 and
BT54928 cell lines metastasize to the lung in vivo, and are clearly
lung tropic by our fingerprint. The HER2+ cell line HCC 1954 is
lung metastatic32 and phenotypically lung tropic. The HER2+
MDA-MB-361 cell line was derived from a brain metastasis,
metastasizes to the brain in mice,38 and is comparatively brain
tropic by our fingerprint. The parental MDA-MB-231 is spontaneously metastatic to many sites upon orthotopic implantation
into the mammary fat pad39 and intracardiac injection,4,40 and
metastasizes to the bone more than to the brain or lung
through the latter technique.40 Our fingerprint identified this
cell line as highly bone tropic (0.62 fractional similarity, 90th
percentile of the randomly generated bone tropism null distribution), significantly greater than the similarity to the brain
and lung fingerprints, reflecting this feature of in vivo behavior
(Fig. 2g and Fig. S5a, ESI†). We focused on this particular aspect
of MDA-MB-231 behavior, as this is the parental cell line from
which the bone, brain, and lung tropic cell lines were derived
by Massagué. As a non-tropic control, the MCF7 cells are only
moderately metastatic, and not tissue-specific,29,30 and were
not tropic to any one tissue based on our fingerprint. Finally,
the HER2+ SkBr3 cells were identified as brain tropic in our
approach, but they are not highly tumorigenic or metastatic to
the brain or other sites in vivo.31 HER2-overexpressing tumors
often spread to the brain in humans, 11 which may explain the
prediction we obtained. However, we would argue that this
example shows that this approach, although highly predictive,
is not 100% accurate, and is only a predictor of tissue selectivity,
not metastatic capability.
When looking more closely, we discovered that the unique
features making up each fingerprint are primarily comprised of
diﬀerential responses to EGF stimulation. In fact, all of the
features in the bone tropic fingerprint are related to EGF
stimulation, 80% for the brain fingerprint, and 62% for the
lung fingerprint. Concurrently, we found that the cell lines with
higher EGFR mRNA expression displayed stronger matching to
just one of the tropic fingerprints than the cell lines with lower
EGFR expression (Fig. 2g and Fig. S5e, ESI†). Using published
proteomic data,41 we discovered a strong correlation between
basal EGFR expression in our cell lines and the CoV of the
in vitro tropism (Fig. S5f, ESI†), confirming this qualitative
trend. Although outside the scope of this study, we speculate
that a more exhaustive screen of additional growth factor
responses, or across diﬀerent ECM protein combinations, could

lend even more specificity for this fingerprinting approach,
potentially resolving the inconsistency we observed in the SkBr3
cell line.
In sum, we compiled sixty-six features of integrin-mediated
phenotypes observed in bone, brain, and lung tropic cell lines
into an in vitro fingerprint, which predicted the in vivo metastasis of other more heterogeneous cell lines. We stress that
this result was impossible to achieve using any single adhesion
or motility measurement, and instead required quantification
of patterns of behavior. Because only some singular features of
two-dimensional cell behavior can predict responses in a more
realistic three-dimensional environment,9 this requirement
was perhaps not surprising. The divergence between two and
three-dimensional phenotypes necessitated this new method of
analysis to accurately connect measurements made in a twodimensional context to in vivo outcomes.
Targeting integrin binding on in vitro ECMs reveals the need
for subtype-specific analysis
Integrins have been explored as cancer therapeutics in preclinical and clinical trials, but many of these drugs have only
shown limited success.42 We hypothesized that this lack of
clinical eﬃcacy may be in part from diﬀerential responses
across the heterogeneity of breast cancer subtypes. Because
we are controlling for integrin-binding on our ECM proteincoupled surfaces, our predictive phenotyping platform provides
a unique opportunity to investigate integrins as therapeutic
targets for metastatic disease. We focused on triple negative
and HER2+ cancer, which both have particularly poor prognosis. As proof of concept, we chose MDA-MB-231 as a
representative triple negative cell line, and used the SkBr3s to
examine HER2+ breast cancer. We focused on integrin subunits
with various aﬃnities to the proteins on each of our ECMs: b1,
which is involved in binding to many proteins across all the
in vitro ECMs; a2, which binds primarily to collagens but also to
laminin (collagen is present on ECMs 1 and 3; laminin is
present on ECMs 2 and 3); and a6, which specifically binds
laminin (present on ECMs 2 and 3).43
We performed the same adhesion and motility experiments
from Fig. 1c in the presence of function-aﬀecting antibodies to
these three integrins. Targeting the function of each integrin
reduced both cell adhesion and migration of the MDA-MB-231
cell line on the three ECMs. When cell adhesion measurements
were plotted against cell migration measurements for each
antibody of interest (as well as without antibody and with
EGF stimulation), the responses clustered together (Fig. 3a
and b). This revealed that the MDA-MB-231 cells were overall
more sensitive to the antibody treatments and EGF stimulation
than they were to the three ECMs. Each antibody had a diﬀerent
potency, resulting in a strong correlation between two measurements of cell adhesion (spreading rate and maximum area) and
motility (migration speed and displacement, Spearman correlations and p-values shown in Fig. 3a and b).
This same clustering of responses around each ECM was not
observed in the HER2+ SkBr3 cell line. Most surprisingly,
treatment with the b1 and a2 integrin antibodies actually

caused an increase in ECM sensitivity in these cells. Specifically, the SkBr3 cells migrated faster and farther on the
collagen-rich ECM 1 (Fig. 3c and d, arrows) in the presence of
both of these function-aﬀecting antibodies. Looking more
closely at videos of the cell behaviors, we determined that the
increase in motility was caused by complete detachment of
individual SkBr3 cells, which would then re-adhere at diﬀerent
locations, essentially hopping along the surface of the biomaterial (Fig. 3e, f and Fig. S6a, Movie S1, ESI†). This behavior
resulted in a small population of cells that had abnormally
fast migration speeds and long displacements (Fig. 3e, f and
Fig. S6a, ESI†). This phenotype was observed most often on
ECM 1 in the presence of the b1 and a2 integrin antibodies, and
rarely in the three other conditions (Fig. S6b, ESI†). This was
never observed in the MDA-MB-231 cells.
This behavior did not resemble traditional adherent cell
motility, and we suspected that these weakly-to-non adherent
cells might be highly invasive in a 3D context, perhaps resembling an amoeboid-type motility.44 When these same b1 and a2
integrin antibodies were administered to SkBr3 cells that were
seeded onto ECM 1 overlaid with a 3D collagen gel, we observed
increased upward 3D invasion by three to four fold compared to
the control (Fig. 3g and Fig. S6c, ESI†). The SkBr3 cell line has
lower integrin protein expression of each of these integrin
subunits in comparison to the MDA-MB-231 cell line,45,46 which
is potentially responsible for the detachment and invasion
phenotypes. However, there were no diﬀerences in b1 integrin
mRNA expression (Fig. S7a, ESI†), suggesting that a proteomic,
but not a genomic analysis could have predicted this result. We
propose that the motility and invasion of some cancer cell lines
can actually be increased when targeting integrins,47 potentially
limiting the eﬃcacy of this class of therapeutics in some
patients. The striking diﬀerences in antibody responses of the
triple negative MDA-MB-231 and HER2+ SkBr3 cell lines highlight the heterogeneity in response to integrin therapeutics
observed across diﬀerent breast cancer clinical subtypes, potentially explaining the limited eﬃcacy of these drugs thus far.
Integrin binding and expression dictates tropism
The b1, a2, and a6 integrin subunits each have a reported role in
cancer: high expression of both b1 (ref. 48) and a6 (ref. 49)
integrins drives tumorigenicity and metastasis, while a2 integrin is a tumor suppressor.50 Although all three integrins appear
important in overall patient prognosis, none have been directly
connected with tissue-specific metastasis. Given the results in
Fig. 2, where tropic cells shared similar integrin-mediated
phenotypes, and Fig. 3, where the triple negative MDA-MB-231
and HER2+ SkBr3 cell lines had divergent responses to integrin
targeting, we hypothesized that targeting b1, a2, and a6 integrins
could shift the observed in vitro tropism of these cell lines.
We compiled the adhesion and motility measurements for the
MDA-MB-231 and SkBr3 cell lines that were performed in the
presence of integrin antibodies into our predictive fingerprint.
This treatment with integrin antibodies, which lowers the binding
ability with these integrin subunits, shifted the tropism predictions of both cell lines (Fig. 4a and b). In the MDA-MB-231 cells,

Fig. 3 Correlations between adhesion and migration responses identify potent integrin antibodies in vitro. Pairwise comparisons between adhesion and
migration measurements in the (a, b) MDA-MB-231 and (c, d) SkBr3 cell lines across normal, EGF-stimulated, and integrin antibody conditions. Arrows
highlight conditions where integrin antibodies increased migration metrics. Spearman correlations are indicated on each plot with two-tailed p-values.
Circle: ECM 1; square: ECM 2; triangle: ECM 3; black: normal; green: EGF; blue: anti-b1 integrin; red: anti-a2 integrin; orange: anti-a6 integrin. (e, f) SkBr3
migration mechanisms are displayed via 10 random cell paths under (e) normal and (f) anti-b1 conditions. Red paths identify cells detaching and adhering
elsewhere on the surface. Inset: representative images of cell morphology. Scale bar is 25 mm. (g) Individual cells that invaded into an overlaid 3D collagen
gel from the ECM 1 surface after 48 hours. Bar indicates mean distance invaded of all invading cells. Inset: schematic of cells invading upward from the
ECM surface into an overlaid gel.

treatment with any of the integrin antibodies shifted the tropism
from bone to brain (Fig. 4a). In other words, blocking binding via
b1, a2, or a6 integrins made the MDA-MB-231 cells less similar to
the bone tropic fingerprint, and instead, they more resembled the
brain tropic cell subpopulation (compare the tropism category
containing the highest black bar with the tropism category
containing the highest colored bars for each integrin). The SkBr3
cells shifted from brain to bone tropic upon b1 integrin inhibition,
they became equally brain and lung tropic when a2 integrin was
blocked, and a6 integrin targeting had no eﬀect (Fig. 4b). Just as
we found in Fig. 3, the MDA-MB-231 cell line was far less sensitive
to diﬀerences in ECM during integrin targeting than the SkBr3
cell line. Interestingly, the only response that was shared between
the MDA-MB-231 and SkBr3 cell lines was the ‘‘null eﬀect’’ of

targeting a2 and a6 integrins on lung tropism. Overall, these
results suggest that targetingany one of these integrins may
eﬀectively prevent bone metastasis in the triple negative cell line,
while b1 integrin may be an eﬃcacious therapeutic target to
prevent brain and lung (but not bone) metastasis in the HER2+
cell line.
For this approach to have significant impact, it must be
compared with clinical patient outcomes. We analyzed gene
expression data from 630 breast cancer patients with known
metastatic outcomes (combined from GSE 2034, GSE 2603, GSE
5327, GSE 12276; includes 214 bone metastases, 35 brain
metastases, 101 lung metastases). We first determined whether
expression of these integrin genes was associated with tissuespecific metastasis in the clinic (Fig. 4c–e), and then compared

Fig. 4 Integrin binding and gene expression predict breast cancer metastasis. Integrin antibodies shift tropic fingerprinting of (a) MDA-MB-231 and (b)
SkBr3 cell lines. Compare the tropism containing the highest black bar (normal) with the category containing the highest value for each colored bar (blue:
b1, red: a2, orange: a6 integrin). (c–e) Magnitude of integrin gene expression dictates (c) bone, (d) brain, and (e) lung metastasis clinically (analysis of GSE
2034, GSE 2603, GSE 5327, GSE 12276). (f) Left, effect of b1, a2, and a6 integrin gene expression on clinical metastasis in all patients, only triple negative
patients, and only HER2+ patients. Right, effect of b1, a2, and a6 integrin antibodies on tropic fingerprint in the MDA-MB-231 (triple negative) and SkBr3
(HER2+) cell lines. Red: high expression or binding predicts for increased metastasis; blue: low expression or binding predicts for increased metastasis;
white: no effect. (g) Heat map displaying integrin genes that significantly predict for tissue-specific metastasis in patients. Blue: low expression of the
gene predicts for increased risk of metastasis; red: high expression of the gene predicts for increased risk of metastasis; white: no effect on metastasis.
Asterisks indicate statistically significant relationships, but other clearly visible trends are included for completeness. Abbreviations: Bo: bone metastasis;
Br: brain metastasis; Lu: lung metastasis.

this with the results predicted from our in vitro fingerprinting
approach when targeting integrin binding (Fig. 4a and b). As
one example, the gene expression data sets revealed that low a2
integrin expression in the primary tumor correlates with higher
rates of brain metastasis, and, similarly, decreasing a2 integrin
binding significantly increased the MDA-MB-231 brain tropic
phenotype in vitro (compare Fig. 4a, increase in brain tropism
from black to red, with Fig. 4d, increased risk of brain metastasis from black to red). As another example, a6 integrin has
no effect on lung metastasis, in both clinical patient outcomes
and the tropism of both cell lines (Fig. 4a and b). In this case,
when these same patients are classified into clinical subtypes

using published annotations,4,51 and survival analysis is
repeated in these smaller, specific patient populations, the
subtype-specific trends in tropism match the behavior of
corresponding the cell line we examined (Fig. 4f). We want to
stress that this latter result was only one of two shared outcomes we found between the triple negative and HER2+ cell
lines, highlighting the need for individual analysis of subtypes,
as demonstrated in Fig. 3.
Interestingly, when this clinical analysis is expanded to
examine all integrin subunits, many are associated with metastasis to the brain, bone, or lung, but these same genes are not
conserved within the triple negative and HER2+ subtypes

(Fig. 4g and Fig. S7b, ESI†). Strong examples are a1, a3, and b2
integrins, where altered expression of these genes is correlated
with tropism to a specific tissue across breast cancer broadly,
but they are not correlated with tropism within these two
subtypes. Instead, diﬀerent integrin subunit genes are correlated with tissue-specific metastasis within each of these subtypes. As two examples, low a8 integrin expression is correlated
with bone metastasis in the HER2+ subtype, and high b1
integrin expression is correlated with lung metastasis in the
triple negative subtype.
When we compared our in vitro phenotyping approach to this
existing gene data set, we found that our in vitro tropism
responses imperfectly correlated with these genetic indicators.
High b1 expression is associated with poor prognosis,48 and in our
work, targeting b1 integrin makes the MDA-MB-231 cell line much
less bone tropic, matching this result (Fig. 4a). However, the SkBr3
cell line significantly increased in bone tropism upon targeting b1
integrin, (Fig. 4b), and our clinical analysis surprisingly showed
that the magnitude of b1 integrin gene expression is not predictive
of bone metastasis in patients (Fig. 4c). However, the divergent
responses of the two candidate cell lines, from diﬀerent clinical
subtypes, combine to match the clinical pattern. Although our b1
integrin targeting results were not predictive of these clinical
outcomes, we emphasize that this highlights the divergence
expected between a genetic-focused approach and a proteinbased, functional approach, as we have taken here.
In sum, we have used a simple integrin-mediated phenotyping approach to predict breast cancer metastasis in a large
panel of cell lines, and we implicate b1, a2, and a6 integrin
binding in tissue-specific spread distinctly across several disease subtypes, a phenomenon that is prevalent across many
integrin gene-tissue combinations in clinical patient populations (Fig. 4g and Fig. S7b, ESI†). Importantly, our integrin
targeting results provide many insights not apparent in gene
expression data, highlighting the need for functional, proteincentric screens of cell behaviors. We emphasize the utility of this
phenotyping approach as quick, bench-top screening tool that
can be used to predict in vivo outcomes. Here, we have illustrated
this functionality by predicting metastatic outcomes and identifying biomarkers potentially overlooked when analyzing gene
data sets from heterogeneous clinical patient populations.

Discussion
Extracellular matrix (ECM) properties, such as tissue stiﬀness,7
local growth factors,52 stromal cells,6,53 and ECM proteins,5,10,54
can each individually promote metastasis. However, we are only
beginning to understand the role of each of these properties in
tissue-specific metastatic colonization.5,6,52,54 To truly understand
the microenvironmental factors that mediate metastasis, each
factor must be systematically isolated from other cues, and
investigated functionally in a controlled system that closely represents the in vivo microenvironment. While others have used
adhesion phenotyping to diﬀerentiate metastatic and nonmetastatic cells,10 and tropic subpopulations,34 these studies have

either used end-point analyses or have included multiple convoluted microenvironmental factors. The biomaterial platform
we designed overcomes these limitations by mimicking some of
the biochemical complexity present in in vivo ECMs, while
limiting microenvironmental cues to only those ECM proteins
presented by the system, with growth factors supplemented as
desired. This can then be used for observing diﬀerences in
adhesion and motility resulting from diﬀerential binding to
these multi-protein ECMs.
We propose this system as a potential bridge between the
overwhelming complexity of in vivo observations and simple
in vitro cell biology, without the need for expensive or labspecific 3D models. The first challenge we noted was that
genomics is the increasingly popular approach for identifying
cancer biomarkers due to its ease and increasingly low cost,
facilitating large-scale patient-specific analysis. However, gene
expression does not necessarily correlate with protein expression
or function. Therefore, we attempted to connect gene-centric
patient data with a protein-centric cell screening approach.
Breast cancer was a suitably complex target to study, as it is a
notoriously heterogeneous disease.11 This heterogeneity may be
why integrins were not consistently strong genetic biomarkers
across large, diverse patient populations (Fig. 4). Our proteincentered approach mirrored this inconsistency between the
SkBr3 and MDA-MB-231 cell lines (Fig. 3 and 4), and we
quantified significant diﬀerences in cell adhesion and motility
between the three MDA-MB-231 tropic subpopulations (Fig. S3,
ESI†), which have minimal diﬀerences in integrin gene expression (Fig. S7a and c, ESI†).2–4
The immediate conclusion is that diﬀerences in gene expression of integrin subunits alone is not suﬃcient to mediate
metastasis to diﬀerent tissues. This remains an open question,
as gene expression of several integrins was strongly correlated
with tropic metastasis in patients (Fig. 4g), but most of these
integrins have not yet been functionally examined in vivo. For
those that have, the in vivo reports we found did not match the
clinical correlations in our analysis of the gene data sets. For
example, a3b1 integrin binding is known to mediate lung
metastasis in rats and mice.18,19 However, high a3 integrin
gene expression showed only a non-significant correlation with
lung metastasis, and only when we isolated the analysis to
triple negative patients. Across all subtypes of patients, high a3
integrin gene expression actually more highly correlated with
bone metastasis (Fig. 4g). As another example, avb3 integrin has
been linked to bone metastasis in rats,17 however, b3 integrin
gene expression in these data sets does not predict for bone
metastasis, and av integrin gene expression is only more
strongly associated with bone metastasis in the triple negative
and HER2+ subtypes than across all patients (Fig. 4g). It is
important to note that clinical tumor samples contain stroma,
are often contaminated with immune cells, fibroblasts, and
epithelial cells,55 and even the best dissection techniques only
produce tumor contents near 70%, 3 which could skew genetic
analysis. We stress that based on this conflict between our data
and the genetic analysis we performed, alongside obvious
conflicts between these gene data sets and literature reports,

successful risk assessments of tropic metastasis require an
integrated proteomic and genetic approach.
Our results suggest that tropism depends more upon how
cells are able to use their integrins to bind to the ECM, rather
than variations in gene expression, even in genetically similar
cell lines. We propose that this type of functional screen, across
many heterogeneous cell lines, and many phenotypes, is independent of these conflicts observed between genetic and proteomic analyses. This is demonstrated by the fact that the bone,
brain, and lung tropic phenotypes we obtained were wellconserved across cell lines that share the same preferred
metastatic site, but that have very diﬀerent integrin gene and
protein expression (Fig. 2g). As an example, the MDA-MB-231
and SUM1315 MO2 cells are both bone metastatic in mice,2,37
and both matched our bone fingerprint, even though the
MDA-MB-231 cell line has significantly higher surface expression of a2 and a5 integrins, and lower expression of avb3, than
the SUM1315 MO2 cell line.56 Others have shown that metastasis depends upon activation, rather than simply expression,
of integrins.57–59 It is known that splicing variation of a single
integrin can initiate cancer stem cell plasticity and likely
impact tropism.16 Taken together, this suggests that understanding the true role of integrins in mediating tropism
requires a functional analysis of how metastatic cells interact
with the tissue site, as we have taken here, rather than a limited
view of only gene expression profiles.
One study took a similar approach to ours and examined
cancer cell behavior on diﬀerent biomaterial surfaces, but
focused on stiﬀness as the driving force.7 They found that
measurements of cell area were not predictive of metastasis,
but there was a weak correlation between both migration and
proliferation with metastatic site preference.7 Upon our own
closer examination, their data shows that tropic subpopulation
cell areas were more sensitive to the biomaterial environments
than the non-tropic subpopulations, consistent with our results
(Fig. S4a, ESI†). This suggests that applying our approach to
other microenvironment cues, such as material stiﬀness, would
provide further insight into the biophysical regulation of tropism
and add another dimension to the fingerprint reported here.
Integrins are attractive therapeutic targets for metastasis
because they mediate adhesion to the tissue microenvironment,
can confer resistance to treatments, and drive disease progression
and stemness.16,60,61 However, integrin-targeted therapeutics have
experienced limited clinical success,42 and some potentially
dangerous outcomes have been reported.62,63 Others have
shown that inhibiting b1 integrin can reduce primary tumor
growth, but this subsequently promotes lung metastasis by
switching the migration mode of triple negative 4T1 mouse
breast cancer cells from collective to single cell migration,
observed both via knockdown and antibody targeting.63 Similar
to these results, we saw both eﬃcacious and dangerous cell
adhesion and motility phenotypes when we targeted integrin
binding on our ECMs. b1 and a2 integrin antibody treatment on
ECM 1 prevented spreading, but increased both 2D motility and
3D invasion of the SkBr3 cell line (Fig. 3c–g). In the highly
metastatic MDA-MB-231 cell line, our b1, a2, and a6 integrin

antibodies each reduced adhesion and motility (Fig. 3a and b),
but also dangerously increased the phenotypic similarity to
brain tropism (Fig. 4a). These dangerous phenotypes may result
from plasticity and adaptability of metastatic cells when integrins are targeted,62,64 which is potentially responsible, in part,
for the lack of clinical success of integrin therapeutics.
These results highlight the known heterogeneity challenge
in breast cancer, and there is a ground swell toward personalized therapeutics. As proof of concept toward using our platform for discovery of treatments for metastasis in this
heterogeneous disease, we examined cell lines from two clinical
subtypes with poor prognosis, and found that they displayed
striking diﬀerences in response to integrin antibodies. In our
fingerprinting results, these cell lines only shared two of nine
possible responses to the integrin antibodies, suggesting
subtype-specific roles for b1, a2, and a6 integrins in bone, brain,
and lung metastasis. The MDA-MB-231 tropism was equally
aﬀected by each of these integrin antibodies, while the SkBr3
cell line was much more sensitive to b1 integrin targeting than
to targeting a2 or a6 integrins. Supporting the subtype-specific
responses we observed, there is in vivo evidence for distinct
roles of the same integrin in tumorigenesis and metastasis in
diﬀerent types of breast cancer.64 In PyV-MT tumors, b1 integrin
is required for tumor initiation. However, in mice that also
express active erbB2 (HER2), b1 integrin is only necessary to
mediate lung metastasis, while tumorigenesis is independent
of b1 integrin.64 In our work, b1 integrin targeting had no eﬀect
on the MDA-MB-231 lung tropism, but significantly decreased
lung tropism in the HER2+ SkBr3 cell line. However, of the
eleven cases where integrin gene expression predicts for tropic
metastasis in the clinic, only two were conserved for both the
triple negative and HER2+ patient subpopulations (Fig. 4). This
indicates that integrins are not conserved biomarkers across
the entire heterogeneous patient population, necessitating
subtype- or even tumor-specific screening to identify successful
integrin therapeutics. We suggest that this type of functional
screening would be capable of identifying eﬃcacious tumorspecific therapeutics, providing additional insight in combination with current genetics-based approaches.

Conclusions
Here, we developed a simple, yet robust in vitro biomaterial
platform that allowed us to quantify many diﬀerent cell phenotypes associated with adhesion and motility in order to take a
comprehensive view of how integrin–ECM interactions regulate
bone, brain, and lung metastasis. Importantly, these results
would not have been realized by simply looking at individual
measurements, and required us to instead quantify patterns of
measurements. This compiled pattern of measurements created
a phenotypic fingerprint, which is dependent only on integrin
binding to the ECM, and can predict integrin-mediated metastatic spread in cell lines. Our results suggest that targeting
integrins across the heterogeneous breast cancer clinical subtypes is not appropriate (Fig. 3 and 4), potentially explaining the

lack of success of integrin-targeted therapeutics thus far. Importantly, our results are largely independent of integrin gene or
protein expression, highlighting the need for this type of functional approach, particularly when comparing among different
breast cancer subtypes. We emphasize the utility of this biomaterial platform to screen integrin–ECM interactions rapidly
and reproducibly, and by collectively quantifying patterns of
phenotypes en masse, the ability to predict in vivo fate with a
simple in vitro approach.

Materials and methods
Cell culture
Human breast cancer cell lines MDA-MB-231, BT549, MCF7,
and SkBr3 were generous gifts from Shannon Hughes at the
Massachusetts Institute of Technology. Highly metastatic MDAMB-231 variants, isolated from in vivo selection, were kindly
provided by Joan Massagué.2–4 These cell lines preferentially
metastasize to the bone (1833 BoM), brain (831 BrM2a) or lung
(4175 LM2). All were routinely cultured in Dulbecco’s Modified
Eagle’s Medium supplemented with 10% fetal bovine serum
(FBS), 1% penicillin–streptomycin (P/S), 1% L-glutamine, and
1% non-essential amino acids. The MDA-MB-361, SUM1315
MO2, MDA-MB-468, and HCC 1954 cell lines were provided
by Mario Niepel at Harvard Medical School. SUM1315 MO2
cells were cultured in Ham’s F-12 medium supplemented with
5 mg ml-1 insulin, 10 ng ml-1 EGF, 10 mM HEPES, 10% FBS,
and 1% P/S. MDA-MB-361 cells were cultured in Leibovitz’s L-15
medium with 20% FBS and 1% P/S. MDA-MB-468 cells were
cultured in Leibovitz’s L-15 medium with 10% FBS and 1% P/S.
HCC 1954 cells were cultured in RPMI medium with 10% FBS
and 1% P/S. With the exception of the MDA-MB-361 and MDAMB-468 cells, which were cultured without supplemental CO2, all
cell lines were cultured at 37 1C and 5% CO2. All cell culture
supplies were purchased from Life Technologies (Carlsbad, CA).
Preparation of ECMs
Glass coverslips (15 mm and 18 mm diameter, Fisher Scientific,
Agawam, MA, USA) were oxygen plasma treated (Harrick
Plasma, Ithaca, NY, USA), and silanized through vapor phase
deposition of (3-aminopropyl)triethoxysilane (Sigma-Aldrich,
St. Louis, MO, USA) at 90 1C for a minimum of 18 hours.65
The coverslips were rinsed sequentially in toluene (Fisher
Scientific), 95% ethanol (Pharmco-AAPER, Brookfield, CT,
USA), and water, and dried at 90 1C for one hour. They were
then functionalized with 10 g L-1 N,N-disuccinimidyl carbonate
(Sigma-Aldrich) and 5% v/v diisopropylethylamine (SigmaAldrich) in acetone (Fisher Scientific) for two hours.66 Coverslips were rinsed three times in acetone and air-dried. ECM
protein cocktails were then covalently bound to the glass
coverslips through reactive amines,67 using cocktails that were
inspired by the ECM of secondary sites as follows: ECM 1 (bone):
5 mg cm-2 of 99% collagen I and 1% osteopontin; ECM 2 (brain):
1 mg cm of 50% fibronectin, 25% vitronectin, 20% tenascin C,
and 5% laminin; and ECM 3 (lung): 2 mg cm-2 of 33% laminin,
-2

33% collagen IV, 15% collagen I, 15% fibronectin, and 4%
tenascin C (all weight%). Rat-tail collagen I and natural mouse
laminin were purchased from Life Technologies; human tenascin C, human vitronectin, and human osteopontin from R&D
Systems (Minneapolis, MN, USA); human collagen IV from
Neuromics (Edina, MN, USA); and human plasma fibronectin
from EMD Millipore (Billerica, MA, USA). Coverslips were incubated with proteins at room temperature for three hours, then
with 10 mg cm-2 MA(PEG)24 (Thermo Scientific, Rockford, IL,
USA) for two hours to block non-specific protein adsorption on
any remaining surface area.
An ELISA was used to quantify coupling of collagen III (Fig.
S1, ESI,† 0, 1, 10 and 50 mg cm-2; Fibrogen, San Francisco, CA,
USA). Surfaces were blocked with 10 mg ml-1 BSA (Fisher
Scientific) for 1 hour, reacted with 1 : 200 primary antibody
(Santa Cruz Biotechnology, Dallas, TX, USA) for 1.5 hours,
and then 1 : 200 HRP-conjugated secondary antibody (Abcam,
Cambridge, MA, USA) for 1 hour at room temperature, rinsing
four times with PBS in between each step. Coverslips were
incubated with 0.1 M sodium acetate (pH 5.5) containing 1
mg ml-1 3,3 0 ,5,5 0 -tetramethylbenzidine (Sigma-Aldrich) and
0.05 wt% hydrogen peroxide (Fisher Scientific) and the reaction
proceeded for 30 minutes, then was stopped with 1 M H2SO4
(Sigma-Aldrich). The absorbance at 450 nm was read immediately (Biotech ELx800, Winooski, VT, USA).
Cell adhesion and polarization
Cells were seeded at 4000 cells per cm2 in growth medium,
medium supplemented with 40 ng ml-1 epidermal growth
factor (EGF, R&D Systems) immediately, or with antibody pretreatment, which occurred for 30 minutes prior to seeding. Antib1 integrin (clone P5D2, R&D Systems) was used at
0.83 mg ml-1, and anti-a2 and anti-a6 integrins were used at
3.3 mg ml-1 (a2: clone P5E6, a6: clone NK1-GoH3, both from
Millipore). Cell adhesion was captured through imaging cells
beginning 10 minutes after seeding in an environmentcontrolled Zeiss Axio Observer Z1 microscope (Carl Zeiss,
Oberkochen, Germany) using an AxioCam MRm camera and
an EC Plan-Neofluar 20x 0.4 NA air objective. Images were
taken using AxioVision (Carl Zeiss) at five-minute intervals for a
minimum of 2 hours until cells had reached steady-state.
ImageJ (National Institutes of Health, Bethesda, MD, USA)
was used to trace cell areas using the built-in measurement
function. Spreading rate was defined as the slope of the linear
portion of the area versus time graph during initial adhesion.
Individual cells were marked when they had polarized, and the
fraction of cells that had polarized at 2 hours post-seeding was
quantified for comparison across conditions. Cells that contacted other cells, underwent division or apoptosis, or were not
fully in frame were excluded. N Z 2 independent biological
replicates, N Z 40 cells per condition.
Cell migration
Cells were seeded at 4000 cells per cm2 and given 18 hours to
adhere in growth medium. Seeded cells were treated with a livecell fluorescent dye (CMFDA, Life Technologies), and then

provided fresh medium or medium supplemented with EGF
and/or integrin antibodies (as described above) 4 hours prior to
microscopy. Brightfield and fluorescent images were taken
at 15 minute intervals for 12 hours using an EC Plan-Neofluar
10x 0.3 NA air objective (Carl Zeiss). Cells were tracked using
Imaris (Bitplane, St. Paul, MN, USA) to generate individual cell
paths. Individual cell speeds were determined by calculating a
speed at every 15 minute time interval, then averaging these
over the entire 12 hours. Displacement was defined as the net
change in position of the cell over the total time. Chemotactic
index is the ratio of a cell’s net displacement to path length.
Individual cell average speeds, net displacements, and chemotactic indices were then averaged to determine a mean population value. Cells that contacted other cells, underwent division
or apoptosis, or were not fully in frame for the entire 12 hours
were excluded. N Z 2 independent biological replicates, N Z 90
cells per condition.
Fingerprinting
We quantified adhesion and migration phenotypes for the
three tropic subpopulations, both under normal and EGFstimulated conditions. To create phenotypic fingerprints, first,
we calculated the CoV (standard deviation divided by average,
calculated for final mean values for one measurement across
the three ECMs) for each tropic cell line to determine their ECMsensitivity in each parameter (a CoV greater than 0.1 was
considered ECM-sensitive; Fig. 2a and d). Second, we quantified the fold-change in these metrics in response to EGF
stimulation on each ECM (fold-changes greater than 1.15 or
less than 0.85 were defined as significant; Fig. 2b and e).
Finally, we did all pairwise statistical comparisons across ECMs
(via a one-way ANOVA, described below), and quantified ordering of values (i.e., for normal speed measurements, was ECM 1
greater than, equal to, or less than ECM 2; Fig. 2c and Fig. S4b,
ESI†). We then compiled this data to create a fingerprint of the
66 phenotypes associated with a specific tissue preference
(Fig. 4d and e and Fig. S4b, ESI†). Upon comparison of each
phenotype across the three tropic subpopulations, only those
phenotypes which were identified in just one tropic cell line
were retained, and all phenotypes shared in two or three of the
cell lines were ignored (Fig. 4b–e, and Fig. S4b, ESI,† dark
colors). To validate these fingerprints, we calculated these same
criteria for other cell lines with known in vivo metastasis.
We then overlaid these patterns onto each tropic fingerprint,
and quantified the fractional similarity between each cell line
and the unique phenotypes within these fingerprints (Fig. 2g and
Fig. S5a, ESI†).
Null distributions of bone, brain, and lung tropisms were
generated via a custom code written in MATLAB R2012a (The
MathWorks, Inc., Natick, MA). 10 000 random cell line phenotypes were generated and were compared with the unique
features of the bone, brain, and lung fingerprints to obtain
tropism similarity values. The distributions were ordered,
percentiles assigned, and then the heterogeneous cell lines
were compared with each of these null distributions, matching
their similarity with the percentile associated with this same

similarity in the appropriate null distribution. Because our
distributions were comprised of 10 000 cells with only 13 or
15 possible discrete values, each percentile for a cell line had a
range, illustrated via the error bars in Fig. 2g. Cell lines in the
top or bottom 5% of the ordered distributions were considered
to be significantly higher or lower than the null distribution.
Specifically, the lowest and highest 500 randomly generated
cells had p r 0.05.
Collagen gel invasion
Cells were seeded at 600 cells per cm2 in normal growth medium
and given 12 hours to adhere. Collagen gels (2 mg ml-1) were
made by mixing 5% v/v 1 M NaOH (Fisher Scientific), growth
medium and type I collagen (Life Technologies) on ice. The
medium was removed from the seeded coverslips, and gel
solutions were overlaid onto the cells. Gelation proceeded for
30 minutes at 37 1C and 5% CO2, then 250 ml growth medium
was added to each well. EGF and integrin antibodies were
included in the gel solution and the supernatant medium as
described above. For accurate comparisons, an equal number
of randomly selected positions were observed in all conditions.
N = 2 independent biological replicates, each with three technical replicates, and 25 positions were imaged per technical
replicate.
Gene expression analysis
Gene expression data from primary breast tumors (GSE 2034,
GSE 2603, GSE 5327, and GSE 12276) was retrieved from the
NCBI Gene Expression Omnibus (GEO) database. Each was
RMA normalized using the R platform (Vienna, Austria).68
Datasets were cross-mapped based upon common probes,
and batch eﬀects were corrected with an Empirical Bayes
method using the ComBat algorithm in R.69 Genes represented
by more than one probe were collapsed to the probe with the
highest mean value. For metastasis-free survival analysis,
patients with known metastasis and clinical subtype information were classified into groups of high and low gene expression based upon median expression. Published survival and
clinical subtype information was used.4,51 Survival was analyzed
in Prism v6.0b (GraphPad Software, La Jolla, CA, USA), and
significance was evaluated using a log-rank (Mantel–Cox) test.
To analyze integrin expression in the tropic cell lines, GSE 2603
and GSE 12237 were retrieved from the NCBI GEO database,
RMA normalized, combined using the ComBat algo- rithm as
previously described, and data corresponding to the cell
subpopulations used here (1833, BrM2a, and 4175) were
extracted. Individual integrin genes were extracted, values were
collapsed to the probe with the highest expression, and a heat
map was generated in R.
Reverse-transcriptase PCR
Cells were seeded at 40 000 cells per cm2 and allowed to adhere
to coverslips or tissue culture plastic for a minimum of 18 hours.
Coverslips or wells were washed with PBS prior to detaching cells
with 0.05% trypsin–EDTA (Life Technologies). Total RNA was
extracted using the Genelute Mammalian Total RNA kit (Sigma)

followed by cDNA synthesis using the RevertAid reverse transcriptase protocol, with the exception of using RNasin 40 U mL-1,
(Promega, Madison, WI) as the RNase inhibitor. The amplification was carried out with Jumpstart Taq polymerase according to
the manufacturer’s instructions using a BioRad MJ Mini Personal thermal cycler (Hercules, CA). Primer sequences (Integrated
DNA Technology, Coralville, IA) were as follows:
GAPDH (NM_001256799.1) forward 5 0 -CACTGACACGTTGGC
AGTGG-3 0
reverse 5 0 -CATGGAGAAGGCTGGGGCTC-3 0
Integrin b1: (NM_002211.3) forward 5 0 -CTGGGCTTTAC
GGAGGAAGT-3 0
reverse 5 0 -GTCTACCAACACGCCCTTCA-3 0
Integrin a2: (NM_002203.3) forward 5 0 -CTGGTGTTAGC
GCTCAGTCA-3 0
reverse 5 0 -CCAGGGTGAACCAACCAGTA-3 0
Integrin a6: (NM_001079818.1) forward 5 0 -CGAGGACAAGC
GGCTGTT-3 0
reverse 5 0 -TGACCCCCATCCACTGATCT-3 0
EGFR: (NM_005228.3) forward 50 -CTTCGGGGAGCAGCGATG-30
reverse 5 0 -CAGCTCCTTCAGTCCGGTTT-3 0
Each reaction was analyzed on a 1% agarose gel with
ethidium bromide staining, then visualized under ultraviolet
light using the IN Genius Syngene Bioimaging platform
(Frederick, MD). GAPDH was used as a housekeeping gene.
N Z 2 independent biological replicates.
Statistical analysis and correlations
Statistical analysis was performed using Prism v6.0b. Data are
reported as mean ± standard error. Statistical significance was
evaluated using a one-way analysis of variance, followed by a
Tukey’s post-test for pairwise comparisons. Significance
between proportions (i.e., fraction of cells polarized) was evaluated
with a Fisher’s exact test with two-tailed p-values. To determine
significance between slopes (i.e., spreading rate), an analysis of
covariance was used, with a one-way analysis of variance for
multiple comparisons, defining the sample size as the degrees
of freedom plus one. Spearman correlations were calculated from
mean values paired by condition, and significance was determined using two-tailed p-values. p o 0.05 was considered statistically significant. p o 0.05 is denoted with *, r0.01 with **,
r0.001 with ***, and r0.0001 with ****; p Z 0.05 is considered
not significant (‘ns’).
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